Letters Drug prices

The ranibizumab saga of drug profiteering

BMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a1532 (Published 03 September 2008) Cite this as: BMJ 2008;337:a1532
  1. Andrew C K Lee, clinical lecturer in public health1,
  2. John Radford, director of public health2
  1. 1School of Health and Related Research, University of Sheffield, Sheffield S1 4DA
  2. 2Rotherham Primary Care Trust, Rotherham S66 1YY
  1. andrew.lee{at}sheffield.ac.uk

    The National Institute for Health and Clinical Excellence (NICE) recently sanctioned the use of ranibizumab for age related macular degeneration, having originally concluded it would be cost effective only if limited to treating one eye, which could jeopardise functional vision.1 2 The exorbitant price …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription